Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections. A proof-of-concept

Int J Antimicrob Agents. 2021 Oct 3:106445. doi: 10.1016/j.ijantimicag.2021.106445. Online ahead of print.


Dalbavancin is increasingly used for the treatment of staphylococcal osteoarticular infections. Some population pharmacokinetic studies suggest that a two 1500 mg dosing regimen one-week apart could ensure effective treatment for several weeks. Here we want to provide clinicians with a proof-of-concept of the potential role that therapeutic drug monitoring (TDM) may have in giving a real-time feedback of the estimated duration of optimal treatment of staphylococcal osteoarticular infections with dalbavancin in each single patient.

PMID:34614441 | DOI:10.1016/j.ijantimicag.2021.106445